Equities research analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to post sales of $5.48 million for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Strongbridge Biopharma’s earnings, with the lowest sales estimate coming in at $4.90 million and the highest estimate coming in at $5.99 million. Strongbridge Biopharma posted sales of $2.53 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 116.6%. The business is expected to report its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that Strongbridge Biopharma will report full year sales of $20.30 million for the current year, with estimates ranging from $18.65 million to $21.81 million. For the next fiscal year, analysts expect that the company will report sales of $45.06 million, with estimates ranging from $27.85 million to $59.75 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that that provide coverage for Strongbridge Biopharma.
Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.41. The business had revenue of $4.30 million during the quarter, compared to the consensus estimate of $4.53 million.
NASDAQ:SBBP remained flat at $$5.00 during trading hours on Monday. 610,831 shares of the company were exchanged, compared to its average volume of 416,233. The company has a market capitalization of $226.54 million, a PE ratio of -3.45 and a beta of 0.80. Strongbridge Biopharma has a 12-month low of $3.85 and a 12-month high of $9.25. The company has a debt-to-equity ratio of 8.76, a current ratio of 6.46 and a quick ratio of 6.38.
In other news, major shareholder Associates L.L.C. Cdk bought 14,000 shares of the business’s stock in a transaction on Thursday, July 19th. The stock was purchased at an average price of $4.98 per share, with a total value of $69,720.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last three months, insiders have acquired 910,795 shares of company stock valued at $4,430,231. Company insiders own 4.20% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Lyon Street Capital LLC lifted its position in Strongbridge Biopharma by 126.3% during the 1st quarter. Lyon Street Capital LLC now owns 3,182,149 shares of the biotechnology company’s stock worth $28,162,000 after acquiring an additional 1,776,054 shares during the last quarter. Opaleye Management Inc. lifted its position in Strongbridge Biopharma by 15.1% during the 2nd quarter. Opaleye Management Inc. now owns 1,830,000 shares of the biotechnology company’s stock worth $10,980,000 after acquiring an additional 240,000 shares during the last quarter. BlackRock Inc. lifted its position in Strongbridge Biopharma by 25.4% during the 1st quarter. BlackRock Inc. now owns 1,795,693 shares of the biotechnology company’s stock worth $15,892,000 after acquiring an additional 363,328 shares during the last quarter. Harvest Capital Strategies LLC acquired a new position in Strongbridge Biopharma during the 1st quarter worth $7,301,000. Finally, Park West Asset Management LLC acquired a new position in Strongbridge Biopharma during the 1st quarter worth $6,919,000. 66.89% of the stock is owned by hedge funds and other institutional investors.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
Recommended Story: How Important is Technical Analysis of Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.